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Editorial on the Research Topic
Non-Dopaminergic Systems in Parkinson’s Disease
This collection presents an array of articles addressing the non-dopaminergic mechanisms in
Parkinson’s disease (PD). The dopaminergic system has been the main focus for almost 70 years and
dopaminergic-based strategies still remain the best symptomatic medication to improve quality of
life of parkinsonian patients. However, the interest in non-dopaminergic systems, even beyond
neurotransmission itself, has grown with the accumulation of data showing that PD cannot be
considered as a pure motor disease and understood only through the prism of the nigrostriatal
dopaminergic pathway deficiency. Indeed, the disease progresses through different stages and
damages to other areas and neurochemical systems precede the degeneration of dopaminergic
neurons in the substantia nigra compacta (SNc). The other affected systems participate in the so-
called prodromal or pre-symptomatic phases and contribute to the malfunctioning of the motor and
non-motor circuits. Meanwhile, the non-motor symptoms are increasingly recognized in PD. They
severely alter the quality of life of the patients since they are often more debilitating than the motor
ones and poorly respond to dopaminergic-based therapies. Finally, the studies addressing the
mechanisms of action of antiparkinsonian drugs have revealed that their benefits/side effects
involved mechanisms other than the dopaminergic ones.
Among the classical non-dopaminergic systems involved in PD, Paredes-Rodriguez et al. review the
situation of the noradrenergic system in PD. The noradrenergic system issued from the locus coeruleus
can display severe damages in the disease, presumably before the dopaminergic neurons according to the
hypothesis that the disease progresses from the caudal to the rostral parts of the brainstem. In fact, the
authors recall that the noradrenergic system exerts anti-inflammatory and neuroprotective effect on
the dopaminergic degeneration, and noradrenergic damage can consequently favor the progress of the
disease. Even though the noradrenergic system participates in the mechanism of action of L-DOPA, this
interaction is still unclear and needs further investigation. Mallet et al. review another classical non-
dopaminergic neurotransmitter that has been considered in PD even before dopamine, namely
acetylcholine. The authors focus their analysis on the striatal cholinergic interneurons, which display
specific electrophysiological features but are still difficult to apprehend due to their sparse distribution.
Based on recent literature, the authors report the advantages of using optogenetic approaches possibly
combined with computational studies to investigate the role of cholinergic interneurons in the
physiology and pathophysiology of motor behavior and cognition. On the other hand, the
serotonergic system is one of the most studied non-dopaminergic neurotransmitter systems duringin.org September 2020 | Volume 11 | Article 5938221
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participation in dyskinesia induced by L-DOPA. Schintu et al.
rendered hemiparkinsonian inbred depression-like flinders
sensitive line (FSL) rats and studied their motor responses to
chronic L-DOPA. In contrast to control animals, the
hemiparkinsonian FSL rats did not display sensitization in the
turning response to apomorphine or L-DOPA and only a weak
increase in dyskinesia. The marked differences in L-DOPA-induced
dyskinesia were not associated with modification of the striatal
expression of deltaFosB, a supposed marker of this side effect.
The imbalance of neurotransmitters in the brain is multiple in
part due to degenerative processes away from the SNc. Chambers
et al. recall that some neurons in the pedunculopontine nucleus,
a complex structure housing GABAergic, glutamatergic, and
cholinergic neurons, degenerate in PD. The neuronal degenerative
process in the pedunculopontine nucleus likely participates in
motor disability, notably gait control, and in non-motor
symptoms including sleep deficits, likely due to the innervation of
brain regions different from the SNc. Murueta-Goyena et al. cover
the non-motor symptoms in PD and the GABAergic system
alterations. They recall the participation of GABAergic
mechanisms in various pre-symptomatic disturbances including
olfactory loss, gastrointestinal abnormalities, visual alterations,
cognitive and mood disorders, and make a special emphasis on
rapid eye movement sleep behavior disorder. In this line, Meideiros
et al. describe how neurotoxic and genetic manipulations of rodents
have been utilized to reproduce some of the major sleep
disturbances associated with PD. They further discuss how these
abnormalities can be linked to noradrenaline, serotonin, and orexin
transmission. Several neurotransmitter imbalances operate during
the disease and may participate in the complexity and heterogeneity
of the neuropsychiatric symptoms exhibited by PD patients.
Dujardin and Sgambato propose a thorough examination of the
neuropsychiatric symptoms, including depression, anxiety, apathy,
psychosis, and impulse control disorders, their prevalence and
pathophysiology. The authors deepened their analysis by looking
at the relative contribution of the neurotransmitter systems
dopamine, noradrenaline, serotonin, acetylcholine, GABA, and
glutamate in each of the above-mentioned neuropsychiatric
symptoms in both PD patients and animal models.
Beyond the neurotransmitter systems, there are some
opportunities to develop treatments on specific targets, as theFrontiers in Pharmacology | www.frontiersin.org 2orphan receptors GPR88 and GPR143. Ingallinesi et al. focused
on GPR88, almost exclusively expressed by the medium spiny
GABAergic neurons of the striatum. They used a lentiviral-
mediated knock-down approach of the receptor in the 6-
hydroxydopamine neurotoxic rat model of PD and reported
reduced amphetamine- but increased L-DOPA-induced turning
behavior. These behavioral effects were paralleled by a
normalization of some striatal tissue markers such as GAD67
expression, although the striatal expression of deltaFosB did not
parallel L-DOPA-induced dyskinesia. Yoshio et al. also recall the
interest of another orphan receptor, the GPR143. This receptor has
been proposed as the target of L-DOPA, which would be its
endogenous ligand at least in the retina. The authors review the
possible contribution of GPR143 in PD with a special emphasis on
its colocalization with the protein a-synuclein in Lewy bodies.
The availability of new animal models conditions the progress
of research in the involvement of different neurotransmitters in
the motor and non-motor symptoms of the disease. Gomez-
Benito et al. discuss and provide detailed comparative analysis of
two models based on a-synuclein: the a-synuclein pre-formed
fibril model and the recombinant adeno-associated virus vector-
mediated a-Synuclein overexpression models. The multiplicity
and development of novel models are necessary for progressing
in the understanding of the disease and help to decipher specific
mechanisms. In any case, far beyond the consideration of
dopaminergic neurons of the SNc, PD is a multifactorial
disease evolving before the onset of motor symptoms.AUTHOR CONTRIBUTIONS
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